{"url_path":"/sec/inm/8-k/2026-05-19/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001062993-26-002787-index.html","accession_number":"0001062993-26-002787","cik":"0001728328","ticker":"INM","issuer_name":"InMed Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001062993-26-002787-index.html","primary_entity_key":"0001728328","primary_entity_name":"InMed Pharmaceuticals Inc."},"word_count":233,"has_tables":true,"body_markdown":"**Item 1.01 Entry into a Material Definitive Agreement.**\n\nAs previously reported, pursuant to the terms of certain preferred investment options dated October 26, 2023 (the \"Armistice Preferred Investment Options\"), InMed Pharmaceuticals Inc. (the \"Company\") provided Armistice Capital Master Fund Ltd. (\"Armistice\") with the right to subscribe for and purchase from the Company up to 278,761 common shares in the capital of the Company at an exercise price per common share of $16.60, subject to adjustment (the \"Armistice Exercise Price\"). The Armistice Exercise Price reflects the proportional adjustment to the original exercise price of $0.83 per common share as a result of the Company's previously completed 1-for-20 share consolidation. The Armistice Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities Act\"), and Regulation D promulgated thereunder.\n\nOn May 18, 2026, the Company entered into a preferred investment option amending agreement (the \"Armistice Preferred Investment Option Amending Agreement\") with Armistice to amend the Armistice Exercise Price contained in the Armistice Preferred Investment Options from $16.60 to $0.80.\n\nThe foregoing description of the Armistice Preferred Investment Option Amending Agreement is not complete and is qualified in its entirety by the full text of the Armistice Preferred Investment Option Amending Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this \"Report\") and incorporated herein by reference."}